Cell-Free Protein Synthesis Patents: Who Leads, Trends 2026
- 65.4% of all 182 records in scope sit with just five assignees — the field is far more concentrated than the number of players might suggest.
- Filing peaked in 2020 at 25 records and has since flattened or declined, with the 2022 midpoint at only 6 — a maturing rather than expanding field.
- C12P fermentation claims cover 90.7% of records while bioreactor apparatus (C12M) sits at just 7.1%, pointing to where scale-up hardware claims remain thin.
What the cell-free protein synthesis patent record actually shows
Cell-free protein synthesis strips protein production out of the living cell, using extracts or reconstituted systems to translate RNA into protein without the constraints of cell viability. The patent record in scope spans 182 records filed between 2015 and mid-2026, concentrated in claims around extract preparation, energy regeneration, scale-up and non-natural amino acid incorporation — the four technical levers that determine whether a cell-free system is viable outside a research lab.
Filing activity is not evenly spread: a small number of assignees hold most of the ranked positions, and the technology composition skews heavily toward fermentation and enzymatic synthesis claims over bioreactor hardware. Publication typically lags filing by around 18 months, so the most recent year in any trend line understates real activity.
Filing trends and technology composition
The two views below use the same 182-record scope: one tracks filings over time, the other breaks the corpus down by IPC subclass. Because a single record can carry several IPC classes, the technology shares add up to more than 100% — that is expected and is the same denominator used throughout this page.
A field that peaked in 2020 and has not recovered
Filings ran from 10 in 2017 to a peak of 25 in 2020, then dropped back toward a 2022 midpoint of just 6 and 2 in the most recent (partial) year. That trajectory reads as flat-to-declining rather than an emerging technology still building momentum — though the newest year is always undercounted due to publication lag.
Fermentation claims dominate; bioreactor hardware is thin
C12P (fermentation and enzymatic synthesis) appears in 90.7% of the 182 records in scope, and C12N (microorganisms and genetic engineering) in 78.6% — the two together frame most of the corpus. C12M (bioreactors and enzyme apparatus) appears in only 7.1% of records, a gap worth noting for anyone filing on scale-up hardware rather than the biochemistry itself.
Shares are the percentage of the 182 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell-Free Protein Synthesis with Eureka
This page is one run against one query. Ask Eureka your own question about cell-free protein synthesis and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records and what they represent
Cell-free synthetic incorporation of non-natural amino acids into proteins (US20160115487A1)
The disclosure covers incorporating at least one non-natural amino acid into a polypeptide using a cell-free protein synthesis system that includes a cell-free extract deficient in endogenous tRNA. The method supplies the system with a non-natural amino acid, an orthogonal tRNA and an orthogonal aminoacyl-tRNA synthetase that aminoacylates the orthogonal tRNA with the non-natural amino acid, and it removes endogenous tRNA by ribonuclease treatment.Filed by Bundy, Bradley C. — published 2016-04-28.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7312049B2 | Total amino acid stabilization during cell-free protein synthesis | 38 |
| 2 | US20140295492A1 | Methods for Cell-Free Protein Synthesis | 34 |
| 3 | WO2005098048A1 | Protein expression yield enhancement in cell-free protein synthesis systems by addition of antifoam agents | 32 |
| 4 | US9528137B2 | Methods for cell-free protein synthesis | 26 |
| 5 | US20150259757A1 | Substrate Replenishment and Byproduct Removal Improve Yeast Cell-Free Protein Synthesis | 20 |
| 6 | US20090042244A1 | Protein expression yield enhancement in cell-free protein synthesis systems by addition of antifoam agents | 19 |
| 7 | US20110262946A1 | Monitoring a dynamic system by liquid chromatography-mass spectrometry | 18 |
| 8 | US9701993B2 | Artificial translation/synthesis system | 17 |
| 9 | EP2610348A1 | Novel artificial translation/synthesis system | 17 |
| 10 | US20040121346A1 | Designing and construction of transcription template for synthesizing cell-free protein, and dilution batch-t… | 17 |
Citation counts inside a searched corpus favour older records by construction — read them as a signal of influence on later filings, not as a measure of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four figures from the dataset carry direct implications for where to file next and where prior art is already dense.
The leaderboard is short
Five assignees hold 119 of the 182 records in scope, and the top 10 combined reach 88.5%. New entrants are filing into a field where the claim space near core extract-preparation and energy-regeneration methods is already occupied by a handful of players.
Filing has cooled since 2020
The trend runs from 10 records in 2017 up to 25 in 2020, then down to a 2022 midpoint of 6. Several of the most active historical filers show 0 filings in the latest year, consistent with a field consolidating around established claims rather than expanding.
Biochemistry is crowded; hardware is not
C12P (fermentation and enzymatic synthesis) sits in 90.7% of records and C12N in 78.6%, while C12M (bioreactor and enzyme apparatus) appears in only 7.1%. Scale-up hardware and reactor design claims sit on far less prior art than the underlying biochemical methods.
Europe and the US lead filing routes
EPO records (50) narrowly outnumber US filings (47), with WIPO/PCT applications (40) close behind and Canada, Australia and Austria trailing well behind. Any freedom-to-operate review needs to clear all three lead jurisdictions, not just the US.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell-free protein synthesis, with the prior art for and against each one.
Who holds the ground, and where it is still open
The ranked assignee list covers 57 companies across the 182 records in scope — not a top-50 or top-100 cut, but the entire ranking the dataset returns. A small number of names account for most of the volume, and recent-year momentum data shows several of the largest historical filers have gone quiet.
One filer sits well ahead of the field
The leading assignee holds 32 of the 182 records in scope, roughly double the fifth-place holder's 16. That gap is unusual for a field with 57 ranked companies and suggests an early, sustained filing programme rather than a recent land grab.
A steep drop after the top five
Fifth place holds 16 records and tenth place drops to 6 — a fast taper rather than a gradual one. Below the top ten, the remaining 47 ranked assignees share the residual 11.5% of records, a long tail of single- or few-filing entrants.
Collaboration is limited and academic-industry paired
Only 10 co-assignee pairs appear in the dataset, the strongest linking a university filer with an industrial partner at a count of 7. Most of the remaining pairs cluster around research-institute and corporate combinations, suggesting joint filing is the exception rather than the norm in this field.
| Assignee | Recent year | YoY |
|---|---|---|
| Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V. | 0 | -100% |
| Northwestern University | 0 | -100% |
| The Board of Trustees of the Leland Stanford Junior University | 0 | — |
| RIKEN Co., Ltd. | 0 | — |
| Sutro Biopharma, Inc. | 0 | -100% |
| Nuclera Ltd. | 0 | -100% |
| Wakenyaku Co., Ltd. | 0 | — |
| LanzaTech Inc. | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying where a new filing has room to stand.
Check freedom-to-operate against the top five
With 65.4% of records held by five assignees, any new filing on extract preparation or energy regeneration should be checked against those portfolios first, not the full 57-name ranking.
Run a freedom-to-operate checkLook at bioreactor and scale-up apparatus claims
C12M coverage sits at just 7.1% of records against 90.7% for core fermentation claims — a real gap for anyone filing on hardware rather than biochemistry.
Explore white space in EurekaTrack the assignees that have gone quiet
Several of the most historically active filers show 0 filings in the latest year. Confirming whether that reflects a strategy shift, a licensing move, or simple publication lag matters before assuming the space is open.
Monitor assignee activityCommon questions about cell-free protein synthesis patents
The ranked assignee list covers 57 companies across the 182 records in scope, and it is heavily front-loaded: the leading assignee holds 32 records, roughly double the fifth-place holder's 16. The top five assignees combined account for 65.4% of all records, and the top ten reach 88.5%. Below that, the remaining 47 ranked assignees share a long tail of single- or few-filing entries, so due diligence should focus first on the leading names rather than the full list.
Not currently. Filings rose from 10 in 2017 to a peak of 25 in 2020, then fell back to a 2022 midpoint of just 6, with only 2 recorded in the most recent partial year. That pattern reads as flat-to-declining rather than an emerging technology gaining momentum, though publication typically lags filing by around 18 months so the newest year is always undercounted. Several of the historically largest filers also show zero filings in the latest year tracked.
Fermentation and enzymatic synthesis methods, classified under IPC subclass C12P, appear in 90.7% of the 182 records in scope, and microorganism/genetic engineering claims under C12N appear in 78.6%. Peptide and protein claims (C07K) and enzyme/DNA testing claims (C12Q) follow at 22.0% and 18.7% respectively. Bioreactor and apparatus claims (C12M) are comparatively rare at 7.1%, which is where hardware-focused filers face less prior art density.
The clearest gap sits in bioreactor and scale-up apparatus claims (C12M), which cover only 7.1% of the 182 records despite fermentation biochemistry claims covering 90.7%. Combinatorial library screening formats (C40B) and material analysis methods (G01N) are similarly thin at 4.4% each. A first claim in these areas would likely focus on reactor design or continuous-flow energy regeneration hardware rather than restating extract-preparation biochemistry that is already densely claimed.
The European Patent Office leads with 50 records, followed closely by the United States with 47 and the WIPO/PCT route with 40. Canada (15), Australia (7) and Austria (4) trail well behind. Because EPO and US filings are close in volume and PCT applications are substantial, a freedom-to-operate review for this field needs to clear all three major routes rather than the US alone.
Research Cell-Free Protein Synthesis in depth with Eureka
Go past this page: query the whole cell-free protein synthesis corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.